BG-C477 / BeOne Medicines - LARVOL DELTA

A Study of BG-C477 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=310 | Recruiting | Sponsor: BeOne Medicines | N=21 ➔ 310 | Trial completion date: Oct 2028 ➔ Dec 2027 | Trial primary completion date: Oct 2028 ➔ Dec 2027

Enrollment change • First-in-human • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

BG-C477, a novel topoisomerase 1 inhibitor-based ADC, exhibits antitumor activity in carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing preclinical models (AACR 2025) - P1 | "Moreover, BG-C477 exhibited superior antitumor efficacy in GC and CRC PDX models that anti-CEA DM4 ADC was ineffective.In summary, BG-C477 is a promising CEA targeting ADC with great anti-tumor activity across multiple types of tumors. The first in human study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 is ongoing (NCT06596473)."

Preclinical • Colorectal Cancer • Embryonal Tumor • Gastric Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CEACAM5

A Study of BG-C477 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=21 | Recruiting | Sponsor: BeiGene | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Study of BG-C477 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=21 | Not yet recruiting | Sponsor: BeiGene

Metastases • New P1 trial • Oncology • Solid Tumor